Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis
Journal of Cardiothoracic and Vascular Anesthesia · 2026
DOI: 10.1053/j.jvca.2025.09.043 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cardiothoracic and Vascular Anesthesia, 2026. Verfasst von Matthew Cadd und 6 weiteren Autor:innen. Beteiligte Einrichtung: Anaesthetic Department, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom. Electronic address:…. Hauptthemen laut MEDLINE: Cardiac Surgical Procedures, Blood Coagulation Factors, Factor VIIa, Postoperative Hemorrhage. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
Perioperative hemorrhage during cardiac surgery is a frequent occurrence and can result in significant morbidity and mortality for patients. Prothrombin complex concentrate (PCC) and recombinant factor VIIa (rFVIIa) are therapies that have been used extensively in cardiac surgery with some promise, but with some concern around acute kidney injury (AKI) and thromboembolic disease with rFVIIa use. In this meta-analysis and systematic review, the authors summarize the evidence regarding the effects of PCC and rFVIIa on chest tube output, incidence of adverse events, and mortality of adult patients undergoing cardiac surgery. A total of 962 patients from seven retrospective observational studies were included in the pooled analysis. There was a significant reduction in the primary outcome: total chest tube output (mean difference: -301.01 mL, 95% confidence interval [CI] -550.54 to -51.48). PCC was associated with a significant reduction in total thromboembolic disease (odds ratio: 0.55, 95% CI 0.34 to 0.89), deep vein thrombosis (odds ratio 0.28, 95% CI 0.15 to 0.52), and cryoprecipitate transfusion (mean difference: -3.93, 95% CI -7.64 to -0.21). There were no significant differences between groups in the incidence of AKI or mortality. Five studies were deemed at moderate risk of bias, and two at serious risk. PCC has been shown to have a beneficial effect on reducing chest tube output and incidence of thromboembolic disease, with no increase in AKI compared with rFVIIa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anaesthetic Department, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom. Electronic address: matthewcadd123@gmail.com.
- Anaesthetic Department, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom.
- Department of Anaesthesia, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
- Department of Anaesthesia, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
Zitieren
APA
Cadd, M., Puntis, D., Bullard, S., Green, S., Kilpatrick, T., Hardy, B., & Seavill, M. (2026). Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia. https://doi.org/10.1053/j.jvca.2025.09.043
Vancouver
Cadd M, Puntis D, Bullard S, Green S, Kilpatrick T, Hardy B, et al. Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia. 2026. doi:10.1053/j.jvca.2025.09.043
BibTeX
@article{Cadd2026,
author = {Cadd, Matthew and Puntis, Daniel and Bullard, Sam and Green, Samira and Kilpatrick, Thomas and Hardy, Ben and Seavill, Miles},
title = {Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis},
journal = {Journal of Cardiothoracic and Vascular Anesthesia},
year = {2026},
doi = {10.1053/j.jvca.2025.09.043}
}
EUVIMED